Pro-Dex, Inc. (NASDAQ:PDEX – Get Rating) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 11,800 shares, a growth of 20.4% from the November 15th total of 9,800 shares. Based on an average trading volume of 9,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.5% of the company's stock are sold short.
Pro-Dex Stock Performance
Pro-Dex stock traded up $0.41 during midday trading on Friday, reaching $17.80. 887 shares of the company's stock were exchanged, compared to its average volume of 7,985. Pro-Dex has a 52 week low of $12.40 and a 52 week high of $26.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.39 and a current ratio of 2.73. The firm has a market cap of $63.72 million, a price-to-earnings ratio of 17.12 and a beta of 0.91. The stock's 50-day simple moving average is $18.07 and its 200 day simple moving average is $17.27.
Get
Pro-Dex alerts:
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Pro-Dex in a report on Thursday. They set a "buy" rating for the company.
Hedge Funds Weigh In On Pro-Dex
Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Pro-Dex by 59.2% during the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 7,762 shares during the period. LSV Asset Management raised its position in shares of Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock valued at $588,000 after buying an additional 4,346 shares in the last quarter. State Street Corp raised its position in shares of Pro-Dex by 5.8% in the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock valued at $197,000 after buying an additional 650 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Pro-Dex in the second quarter valued at approximately $168,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Pro-Dex by 345.6% in the third quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock valued at $48,000 after buying an additional 2,084 shares in the last quarter. Institutional investors own 13.69% of the company's stock.
About Pro-Dex
(Get Rating)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Read More
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
